Amylin's long-delayed diabetes drug gets FDA nod Source: Bristol Herald-Courier Friday 27th January, 2012
WASHINGTON (AP) -- Amylin Pharmaceuticals won approval Friday for its long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company's 7-year old product, Byetta. ...